Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RGKDK
ADC Name
AF-GPL
Synonyms
AF GPL; AFGPL
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Pancreatic cancer [ICD11:2C10]
Investigative
Antibody Name
Anti-ody fragment (AF)
  Antibody Info 
Antigen Name
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (ERBB3)
  Antigen Info 
Payload Name
Gemcitabine and paclitaxel loaded liposome
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.45
ug/mL
BxPC-3 cells
Pancreatic ductal adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.45 ug/mL
Method Description
The cell viability of BxPC3 cells upon formulation treatment were evaluated by MTT assay.
In Vitro Model Pancreatic ductal adenocarcinoma BxPC-3 cells CVCL_0186
References
Ref 1 Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer. Mater Sci Eng C Mater Biol Appl. 2018 Aug 1;89:328-335. doi: 10.1016/j.msec.2018.04.011. Epub 2018 Apr 11.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.